Vildagliptin / Metformin hydrochloride Accord

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

metformin hydrochloride, vildagliptin

Available from:

Accord Healthcare S.L.U.

ATC code:

A10BD08

INN (International Name):

vildagliptin / metformin hydrochloride

Therapeutic group:

Лекарства, използвани при диабет

Therapeutic area:

Захарен диабет тип 2

Therapeutic indications:

Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 и 5. 1 за наличните данни за различни комбинации).

Product summary:

Revision: 2

Authorization status:

упълномощен

Authorization date:

2022-03-24

Patient Information leaflet

                                36
Б. ЛИСТОВКА
37
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
ВИЛДАГЛИПТИН/МЕТФОРМИНОВ
ХИДРОХОЛОРИД ACCORD 50 MG/850 MG ФИЛМИРАНИ
ТАБЛЕТКИ
ВИЛДАГЛИПТИН/МЕТФОРМИНОВ
ХИДРОХОЛОРИД ACCORD 50 MG/1000 MG ФИЛМИРАНИ
ТАБЛЕТКИ
vildagliptin/metformin hydrochloride
(вилдаглиптин/метформинов
хидрохлорид)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар или
фармацевт. Това
включва и всички възможни нежелани
реакции, неописани в тази листовка.
Вижте
точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява
Вилдаглиптин/Метформинов
хидрохолорид Accord и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Вилдаглиптин/Метформинов
хидрохолорид
Accord
3.
Как да приемате
Вилдаглиптин/М
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Вилдаглиптин/Метформинов хидрохлорид
Accord 50 mg/850 mg филмирани таблетки
Вилдаглиптин/Метформинов
хидрохолорид Accord 50 mg/1000 mg филмирани
таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Вилдаглиптин/Метформинов
хидрохолорид Accord
50 mg/850 mg филмирани таблетки
Всяка филмирана таблетка съдържа 50 mg
вилдаглиптин (
_vildagliptin_
) и 850 mg метформинов
хидрохлорид (
_metformin hydrochloride_
) (еквивалентни на 660 mg метформин).
Вилдаглиптин/Метформинов
хидрохолорид Accord 50 mg/1000 mg филмирани
таблетки
Всяка филмирана таблетка съдържа 50 mg
вилдаглиптин (
_vildagliptin_
) и 1000 mg метформинов
хидрохлорид (
_metformin hydrochloride_
) (еквивалентни на 780 mg метформин).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмиранa таблеткa (таблетка)
Вилдаглиптин/Метформинов
хидрохолорид Accord
50 mg/850 mg филмирани таблетки
Жълта, овална, двойноизпъкнала
филмирана таблетка, с вдлъбнато
релефно означение "GG2"
от едната страна и гладка от другата
страна. Размерът на таблетката е
приблизително 20,15 x
8,00 mm.
Вилдаглиптин/Метформинов
хидрохолорид Accord
50 mg/1000 mg филмирани таблетки
Тъмно жълта, овална
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 01-06-2023
Public Assessment Report Public Assessment Report Spanish 17-06-2022
Patient Information leaflet Patient Information leaflet Czech 01-06-2023
Public Assessment Report Public Assessment Report Czech 17-06-2022
Patient Information leaflet Patient Information leaflet Danish 01-06-2023
Public Assessment Report Public Assessment Report Danish 17-06-2022
Patient Information leaflet Patient Information leaflet German 01-06-2023
Public Assessment Report Public Assessment Report German 17-06-2022
Patient Information leaflet Patient Information leaflet Estonian 01-06-2023
Public Assessment Report Public Assessment Report Estonian 17-06-2022
Patient Information leaflet Patient Information leaflet Greek 01-06-2023
Public Assessment Report Public Assessment Report Greek 17-06-2022
Patient Information leaflet Patient Information leaflet English 01-06-2023
Public Assessment Report Public Assessment Report English 17-06-2022
Patient Information leaflet Patient Information leaflet French 01-06-2023
Public Assessment Report Public Assessment Report French 17-06-2022
Patient Information leaflet Patient Information leaflet Italian 01-06-2023
Public Assessment Report Public Assessment Report Italian 17-06-2022
Patient Information leaflet Patient Information leaflet Latvian 01-06-2023
Public Assessment Report Public Assessment Report Latvian 17-06-2022
Patient Information leaflet Patient Information leaflet Lithuanian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-06-2023
Public Assessment Report Public Assessment Report Lithuanian 17-06-2022
Patient Information leaflet Patient Information leaflet Hungarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 01-06-2023
Public Assessment Report Public Assessment Report Hungarian 17-06-2022
Patient Information leaflet Patient Information leaflet Maltese 01-06-2023
Public Assessment Report Public Assessment Report Maltese 17-06-2022
Patient Information leaflet Patient Information leaflet Dutch 01-06-2023
Public Assessment Report Public Assessment Report Dutch 17-06-2022
Patient Information leaflet Patient Information leaflet Polish 01-06-2023
Public Assessment Report Public Assessment Report Polish 17-06-2022
Patient Information leaflet Patient Information leaflet Portuguese 01-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 01-06-2023
Public Assessment Report Public Assessment Report Portuguese 17-06-2022
Patient Information leaflet Patient Information leaflet Romanian 01-06-2023
Public Assessment Report Public Assessment Report Romanian 17-06-2022
Patient Information leaflet Patient Information leaflet Slovak 01-06-2023
Public Assessment Report Public Assessment Report Slovak 17-06-2022
Patient Information leaflet Patient Information leaflet Slovenian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 01-06-2023
Public Assessment Report Public Assessment Report Slovenian 17-06-2022
Patient Information leaflet Patient Information leaflet Finnish 01-06-2023
Public Assessment Report Public Assessment Report Finnish 17-06-2022
Patient Information leaflet Patient Information leaflet Swedish 01-06-2023
Public Assessment Report Public Assessment Report Swedish 17-06-2022
Patient Information leaflet Patient Information leaflet Norwegian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 01-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 01-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 01-06-2023
Patient Information leaflet Patient Information leaflet Croatian 01-06-2023
Public Assessment Report Public Assessment Report Croatian 17-06-2022